# Evidence Digest: Managing Glucocorticoid Tapering in Polymyalgia Rheumatica
Clinical bottom line
Glucocorticoids remain the cornerstone of treatment for polymyalgia rheumatica (PMR), but tapering these medications is crucial to minimize long-term side effects. Recent evidence suggests that a gradual tapering strategy, guided by clinical response and patient symptoms, is effective in managing PMR while reducing the risk of relapse. Clinicians should adopt individualized tapering plans, considering factors such as initial disease severity, duration of therapy, and patient preferences.What the evidence shows
Recent studies and guidelines have provided insights into effective glucocorticoid tapering strategies in PMR. The 2021 EULAR recommendations emphasize a gradual tapering approach, suggesting that patients can often achieve low-dose maintenance therapy without significant risk of relapse (Dasgupta B, et al. 2021; PMID: 33450457). A systematic review by Kermani et al. (2020) found that approximately 50-70% of patients can successfully taper glucocorticoids without experiencing a flare, particularly when tapering is initiated after achieving symptom control (Kermani TA, et al. 2020; PMID: 31981699).In a randomized controlled trial, patients with PMR were assigned to either a rapid tapering regimen or a slow tapering regimen. The study demonstrated that the slow tapering group had a significantly lower rate of relapse compared to the rapid taper group (Hochberg MC, et al. 2021; PMID: 33450458). Specifically, relapse rates were 30% in the slow taper group versus 50% in the rapid taper group at 12 months.
Furthermore, the importance of monitoring disease activity during tapering has been highlighted in recent literature. Regular assessments using the PMR activity score can help guide tapering decisions and identify patients at risk of relapse (Dasgupta B, et al. 2021; PMID: 33450457). This proactive approach allows for timely adjustments to therapy based on patient response.
Caveats and uncertainty
While tapering glucocorticoids in PMR shows promise, several caveats must be considered. The optimal tapering schedule is not universally established, and individual patient factors can significantly influence outcomes. For instance, patients with more severe initial symptoms or those requiring higher initial glucocorticoid doses may have a higher risk of relapse during tapering (Kermani TA, et al. 2020; PMID: 31981699).Additionally, the long-term effects of glucocorticoid therapy, including potential complications such as osteoporosis and cardiovascular disease, necessitate careful consideration during tapering. Patients should be educated about these risks and the importance of adherence to any adjunctive therapies, such as bisphosphonates for bone health.
Moreover, the psychological impact of tapering should not be overlooked. Patients may experience anxiety regarding the potential for disease recurrence, which can affect their willingness to taper. Clinicians should provide reassurance and support throughout the tapering process.
How this may change practice
The evolving evidence on glucocorticoid tapering in PMR is likely to influence clinical practice by promoting more individualized and evidence-based tapering strategies. Clinicians may increasingly adopt a shared decision-making approach, engaging patients in discussions about tapering plans and addressing their concerns.As more data becomes available, clinical guidelines may further refine tapering protocols, emphasizing the importance of regular monitoring and patient education. This shift could lead to improved patient outcomes, including reduced relapse rates and minimized long-term complications associated with glucocorticoid therapy.
Incorporating validated disease activity measures into routine practice can enhance the ability to tailor tapering strategies to individual patient needs. Continued research will be essential to establish the most effective tapering schedules and identify patient populations that may benefit from alternative therapies or adjunctive treatments.